SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria.

Slides:

Advertisements

Similar presentations

Spliceosome mutations in myeloid neoplasms

Advertisements

JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,

Thrombocytopenia or thrombocytosis? Nancy Rosenthal, MD.

The genetic basis of myelodysplasia and its clinical relevance

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.

Increased peripheral platelet destruction and caspase-3– independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients by.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study by Andreas Tiede, Robert Klamroth,

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela.

Myelodysplastic Syndromes

Volume 27, Issue 4, Pages (April 2015)

Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene by A.

Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome

Finding a diamond in the (mouse is) rough

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Sandra Luna-Fineman, Kevin M. Shannon, Susan K

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia:

Topical Sodium Nitrite Is Effective In Reducing Leg Ulcer-Associated Pain In Patients With Sickle Cell Disease by Caterina P. Minniti, Caroline Cantilena,

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

by Mario Cazzola, Marianna Rossi, and Luca Malcovati

Myelodysplastic Syndromes

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous.

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients.

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

Solitary plasmacytoma of bone and asymptomatic multiple myeloma

by Ernest Beutler Blood Volume 98(9): November 1, 2001

The genetic basis of myelodysplasia and its clinical relevance

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,

ROCK and Rho(ll) in bone marrow

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia by Esperanza Such, Ulrich Germing, Luca Malcovati,

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Volume 27, Issue 4, Pages (April 2015)

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes by Raphael Itzykson, Simon Crouch, Erica Travaglino, Alex Smith,

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations by Andrea Pellagatti, Richard.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes by Abdullah Mahmood Ali, Yumin Huang,

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Vindi Jurinovic, Robert Kridel, Annette.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning Yvette L. Kasamon,

by Alex Aleshin, and Peter L. Greenberg

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB (Alliance)‏ by John C. Byrd, Amy S. Ruppert,

Lacramioara Botezatu, Lars C

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes Bartlomiej M. Getta, Ashwin Kishtagari,

Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte.

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Revised International Prognostic Scoring System for Myelodysplastic Syndromes by Peter L. Greenberg, Heinz Tuechler, Julie Schanz, Guillermo Sanz, Guillermo.

A case of lenalidomide-dependent myelodysplastic syndrome

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

by Elisa Rumi, and Mario Cazzola

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela.

Pure red cell aplasia by Robert T. Means Blood

How I treat essential thrombocythemia

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

Cold agglutinin disease

Outcomes in patients with PTCL

Presentation transcript:

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria Ambaglio, Martin Jädersten, Monika Jansson, Chiara Elena, Anna Gallì, Gunilla Walldin, Matteo G. Della Porta, Klas Raaschou-Jensen, Erica Travaglino, Klaus Kallenbach, Daniela Pietra, Viktor Ljungström, Simona Conte, Emanuela Boveri, Rosangela Invernizzi, Richard Rosenquist, Peter J. Campbell, Mario Cazzola, and Eva Hellström Lindberg Blood Volume 126(2): July 9, 2015 ©2015 by American Society of Hematology

Mutation patterns in MDS with ring sideroblasts and <5% bone marrow blasts. Luca Malcovati et al. Blood 2015;126: ©2015 by American Society of Hematology

OS and CI of disease progression of patients with MDS with ring sideroblasts classified according to SF3B1 mutation status. Luca Malcovati et al. Blood 2015;126: ©2015 by American Society of Hematology

OS and CI of disease progression of patients with MDS associated with SF3B1 mutation. Luca Malcovati et al. Blood 2015;126: ©2015 by American Society of Hematology